Recent News

• 03.03.2026 - Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
• 06.25.2025 - Hepion Pharmaceuticals Successfully Completes Application to the OTCQB
• 06.16.2025 - Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer
• 05.12.2025 - Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Recent Filings

• 03.03.2026 - 8-K Current report
• 03.03.2026 - EX-99.1 EX-99.1
• 01.15.2026 - 8-K Current report
• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.22.2025 - 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
• 06.30.2025 - 8-K Current report
• 06.12.2025 - 8-K Current report